Liquid Biopsy Based on Circulating Cancer‐Associated Cells: Bridging the Gap from an Emerging Concept to a Mainstream Tool in Precision Medicine

Jiménez‐Zenteno, Alejandro Kayum; Cerf, Aline

doi:10.1002/adbi.201900164

Cited by 4 publications

(4 citation statements)

References 192 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cfDNA is short, fragmented DNA released from apoptotic or necrotic cancer cells able to provide information on cancer cells genetic and epigenetic mutations (Chen et al, 2020). However, due to its short half-life in the circulation, cfDNA applicability is limited, moreover, its sequencing needs highly sensitive assays such as next-generation sequencing (NGS) (Jimenez-Zenteno and Cerf, 2020). The development of novel techniques for the analysis of low-abundance DNA has allowed to exploit the potential of circulating tumor DNA (ctDNA) as a marker of cancer disease burden, predictor of therapy response or resistance (Cescon et al, 2020).…”

Section: Liquid Biopsymentioning

confidence: 99%

Exosomes: Key tools for cancer liquid biopsy

Panfoli¹,

Bruschi²,

Candiano³

2022

Biocell

View full text Add to dashboard Cite

Precision medicine is based on the identification of biomarkers of tumor development and progression. Liquid biopsy is at the forefront of the ability to gather diagnostic and prognostic information on tumors, as it can be noninvasively performed prior or during treatment. Liquid biopsy mostly utilizes circulating tumor cells, or free DNA, but also exosomes. The latter are nanovesicles secreted by most cell types, found in any body fluid that deliver proteins, nucleic acids and lipids to nearby and distant cells with a unique homing ability. Exosomes function in signalling between the tumor microenvironment and the rest of the body, promoting metastasis, immune remodelling and drug resistance. Exosomes are emerging as a key tool in precision medicine for cancer liquid biopsy, as they efficiently preserve their biomarker cargo. Moreover, exosomes strongly resemble the parental cell, which can help in assessing the oxidative and metabolic state of the donor cell. In this respect, exosomes represent one of the most promising new tools to fight cancer. This review will discuss the clinical applications of profiling exosomal proteins and lipids by high-throughput proteomics and metabolomics, and nucleic acids by next generation sequencing, as well as how this may allow cancer diagnosis, therapy response monitoring and recurrence detection.

show abstract

Section: Liquid Biopsymentioning

confidence: 99%

Exosomes: Key tools for cancer liquid biopsy

Panfoli¹,

Bruschi²,

Candiano³

2022

Biocell

View full text Add to dashboard Cite

show abstract

“…Although this allows for the relative measurement of actin depletion and E of these cells, respectively, for comparison with each other, it may not give a true indication of what these values are in suspension. Indeed, it has previously been shown that the rigidity of cancer cells in suspension may increase to improve their chances of survival in the high-shear regimes that pervade the circulatory system (78)(79)(80). For this reason, future studies might use techniques that examine cell E in circulation such as optical tweezers or Tjunction deformation.…”

Section: Cell Elastic Modulusmentioning

confidence: 99%

The influence of cell elastic modulus on inertial positions in Poiseuille microflows

Connolly

McGourty

Newport

2021

Biophysical Journal

View full text Add to dashboard Cite

“…Unlike standard invasive biopsies, ctDNA sequencing uses a small sample of the patient’s blood. As such it offers a promising non-invasive tool to evaluate tumour heterogeneity permitting multiple sampling and monitoring of treatment response [ 17 ]. Processes such as apoptosis, tissue necrosis, and possibly active secretion by cancerous and normal cells are thought to release nucleic acids (short-double stranded DNA fragments) into circulation [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa “(AI-REAL)”

et al. 2022

View full text Add to dashboard Cite

Background The capacity for invasive tissue biopsies followed by histopathology diagnosis in sub-Saharan Africa is severely limited. Consequently, many cancer patients are diagnosed late and outcomes are poor. Here, we propose to evaluate circulating tumour (ct) DNA analysis (“liquid biopsy”), a less invasive and faster approach to diagnose endemic EBV-driven lymphomas (EBVL) in East Africa. Methods We will evaluate the clinical utility of an already validated ctDNA test prospectively in a head-to-head comparison against histopathology. The primary endpoint is the time from presentation to the specialist centre to a final diagnosis of EBV- Lymphoma. Secondary endpoints include the sensitivity and specificity of liquid biopsy and health economic benefits over histopathology. One hundred forty-six patients will be recruited over 18 months. Patients will be eligible if they are 3–30 years of age and have provided written consent or assent as per IRB guidelines. Tissue and venous blood samples will be processed as per established protocols. Clinical data will be captured securely and in real-time into a REDCap database. The time from presentation to diagnosis will be documented. The sensitivity and specificity of the methods can be estimated within 5% error margin with 95% confidence level using 73 cases and 73 controls. Health-economic assessment will include micro-costing of ctDNA test and histopathology. All results will be reviewed in a multidisciplinary tumour board. Discussion The study evaluates the clinical utility of ctDNA in improving the speed of diagnostic pathways for EBVL in sub-Saharan Africa. Our results would provide proof-of-principle that ctDNA can be used as a diagnostic tool in areas without access to regular pathology, that transfer of the tool is feasible, and that it leads to an earlier and faster diagnosis. The potential clinical and economic impact of this proposal is thus significant. If successful, this study will provide appropriate, and cost-effective diagnostic tools that will promote earlier diagnosis of EBVL and potentially other cancers in countries with restricted healthcare resources. Trial registration Pan African Clinical Trials Registry: PACTR202204822312651, registered on 14th-April-2022.

show abstract

Liquid Biopsy Based on Circulating Cancer‐Associated Cells: Bridging the Gap from an Emerging Concept to a Mainstream Tool in Precision Medicine

Cited by 4 publications

References 192 publications

Exosomes: Key tools for cancer liquid biopsy

Exosomes: Key tools for cancer liquid biopsy

The influence of cell elastic modulus on inertial positions in Poiseuille microflows

A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa “(AI-REAL)”

Contact Info

Product

Resources

About